3,4-dihydroxyphenylethanol has been researched along with Parkinson Disease in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 7 (58.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cappelletto, E; Fongaro, B; Polverino de Laureto, P; Sosic, A; Spolaore, B | 1 |
| Cerezo, AB; Gallardo-Fernández, M; Garcia-Parrilla, MC; Hornedo-Ortega, R; Troncoso, AM | 1 |
| Goyal, B; Goyal, D; Kaur, G; Mankoo, OK | 1 |
| Avila-Acevedo, JG; Garcia-Jimenez, S; Monroy-Noyola, A; Montes, S; Perez-Barron, GA; Rios, LC; Rubio-Osornio, M | 1 |
| Bucciantini, M; Cesaro, S; Leri, M; Palazzi, L; Polverino de Laureto, P; Stefani, M | 1 |
| Brunetti, G; Calabrese, V; Di Rosa, G; Leri, M; Saul, N; Schmitz-Linneweber, C; Scuto, M; Stefani, M | 1 |
| Acquasaliente, L; Bucciantini, M; Fongaro, B; Leri, M; Palazzi, L; Polverino de Laureto, P; Stefani, M | 1 |
| Frost, B; Liu, J; Sun, W | 1 |
| Goldstein, DS; Holmes, C; Jinsmaa, Y; Kopin, IJ; Sharabi, Y; Sullivan, P | 1 |
| Burke, WJ; Li, SW; Nonneman, R; Williams, EA; Zahm, DS | 1 |
| Edwards, DJ; Rizk, M; Spiker, DG | 1 |
| Eisenhofer, G; Harvey-White, J; Kirk, K; Kopin, IJ; Lamensdorf, I; Nechustan, A | 1 |
12 other study(ies) available for 3,4-dihydroxyphenylethanol and Parkinson Disease
| Article | Year |
|---|---|
3,4-Dihydroxyphenylethanol and 3,4-dihydroxyphenylacetic acid affect the aggregation process of E46K variant of α-synuclein at different extent: Insights into the interplay between protein dynamics and catechol effect.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Catechols; Dopamine; Humans; Parkinson Disease; Phenylethyl Alcohol | 2022 |
Hydroxytyrosol and dopamine metabolites: Anti-aggregative effect and neuroprotective activity against α-synuclein-induced toxicity.
Topics: alpha-Synuclein; Dopamine; Humans; Neuroprotection; Parkinson Disease | 2023 |
Unveiling How Hydroxytyrosol Destabilizes α-Syn Oligomers Using Molecular Simulations.
Topics: alpha-Synuclein; Humans; Neurodegenerative Diseases; Parkinson Disease; Phenylethyl Alcohol | 2023 |
Hydroxytyrosol inhibits MAO isoforms and prevents neurotoxicity inducible by MPP+ invivo.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antioxidants; Catecholamines; Corpus Striatum; Dopamine; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenylethyl Alcohol; Protein Isoforms; Rats; Rats, Wistar | 2020 |
Insight into the molecular mechanism underlying the inhibition of α-synuclein aggregation by hydroxytyrosol.
Topics: Acetates; alpha-Synuclein; Antioxidants; Antiparkinson Agents; Cell Line, Tumor; Cell Survival; Cyclopentane Monoterpenes; Humans; Levodopa; Molecular Structure; Parkinson Disease; Phenylethyl Alcohol; Protein Aggregation, Pathological; Protein Binding; Protein Conformation; Proteolysis; Pyrans | 2020 |
Healthspan Maintenance and Prevention of Parkinson's-like Phenotypes with Hydroxytyrosol and Oleuropein Aglycone in
Topics: Acetates; alpha-Synuclein; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Cyclopentane Monoterpenes; Disease Models, Animal; Dopaminergic Neurons; Parkinson Disease; Phenylethyl Alcohol; Polyphenols; Pyrans; Treatment Outcome | 2020 |
Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amyloid; Cell Proliferation; Dopamine; Dopaminergic Neurons; Humans; Oxidative Stress; Parkinson Disease; Phenylethyl Alcohol; Protein Aggregation, Pathological; Protein Multimerization | 2021 |
Oleuropein, unexpected benefits!
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Blood Pressure; Diet, Mediterranean; Humans; Hypertension; Iridoid Glucosides; Iridoids; Mice; Olea; Oxidative Stress; Parkinson Disease; Phenylethyl Alcohol; Rats | 2017 |
3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopamine Agents; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidation-Reduction; Parkinson Disease; PC12 Cells; Phenylethyl Alcohol; Rats | 2016 |
3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glial Fibrillary Acidic Protein; Homovanillic Acid; Immunohistochemistry; Male; Neurons; Parkinson Disease; Phenylethyl Alcohol; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2003 |
Effects of L-DOPA on the excretion of alcoholic metabolites of catecholamines and trace amines in rat and human urine.
Topics: 3-Methoxy-4-hydroxyphenylethanol; Amines; Animals; Dopamine; Gas Chromatography-Mass Spectrometry; Humans; Levodopa; Male; Methoxyhydroxyphenylglycol; Norepinephrine; Parkinson Disease; Phenylethyl Alcohol; Rats | 1981 |
3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Dopamine; Energy Metabolism; Enzyme Inhibitors; Estrogens, Non-Steroidal; Fluorenes; Hydantoins; Isoflavones; Mitochondria; Neurons; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; PC12 Cells; Phenylethyl Alcohol; Rats; Rotenone | 2000 |